Sun Pharma, Cipla will continue to grow: Vivek Mavani, Market Analyst

In a chat with ET Now, Vivek Mavani, Independent Market Analyst and Portfolio Manager, talks about the pahrma sector.

ET Now: How are you approaching defensives the likes of HUL or an ITC even for that matter pharmaceuticals Sun Pharma, Cipla, the likes into the New Year?

Vivek Mavani: The pharma as far as Cipla, Sun or the large cap pharma space is concerned companies which have a significant presence in the domestic market no real issues from that point of view. They will continue to grow in mid double digits or close to or maybe about say 15-20% depending on the product portfolio, on the company.

I would even look at midcap within the pharma space, Ajanta Pharma, pure domestic focussed company would do something like 900 crores of top line this year and about 100 crores profits whereabouts so these are interesting bets to bet on. In the consumer space, the valuations have obviously run up significantly, the growth has supported but they seem to be priced for a certain amount of growth. Any sort of disappointment on delivery of growth in some of these names could spell disappointment. At least outlook at this point of time for whatever visibility is there, disappointment does not seem to be a concern as yet.